# Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

> **NCT03639935** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03639935
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-28
- **Primary completion:** 2023-02-07
- **Final completion:** 2024-04-30
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639935, "Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03639935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*